Molecular Partners (NASDAQ:MOLN – Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Tuesday, August 25th. Analysts expect the company to post earnings of ($0.45) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 25, 2026 at 3:00 AM ET.
Molecular Partners Price Performance
Shares of Molecular Partners stock opened at $4.40 on Friday. Molecular Partners has a 1 year low of $3.53 and a 1 year high of $5.36. The business has a 50 day moving average price of $4.02 and a 200 day moving average price of $4.23. The company has a market capitalization of $177.67 million, a P/E ratio of -2.27 and a beta of 1.08.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on MOLN. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Wednesday, July 8th. HC Wainwright reaffirmed a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Molecular Partners has an average rating of “Hold” and a consensus target price of $8.38.
Institutional Investors Weigh In On Molecular Partners
A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors.
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
See Also
- Five stocks we like better than Molecular Partners
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
